PDCD1 and cancer: Combining ipilimumab with anti-PD-1 agents in melanoma [21] or hepatocellular carcinoma (HCC) [47,48] may increase response rates modestly for resistant cancers but at the cost of a significant increase in the likelihood and severity of irAEs.